Lifenome and Pathomics Health Partner on Precision Health and Longevity in Southeast Asia

NEW YORK - June 10, 2025 - PRLog -- Lifenome Inc., a global leader in AI-driven precision health and longevity technologies, and Pathomics Health, Southeast Asia's rising innovator in molecular diagnostics and personalized health, have announced a strategic partnership to jointly accelerate access to cutting-edge longevity-based solutions across Southeast Asia.

This partnership marks a significant milestone in the evolution of personalized medicine in the region, combining Lifenome's advanced genomics and epigenetics-driven longevity platform with Pathomics' accredited clinical infrastructure and regional diagnostic reach.

We're thrilled to partner with Pathomics, whose regional expertise and diagnostic excellence make them an ideal ally in bringing our vision of personalized, preventive, and longevity-enhancing health solutions to Southeast Asia," said Dr. Ali Mostashari, CEO and Co-Founder of Lifenome. "Together, we are enabling a shift from reactive to proactive health in one of the world's most dynamic and diverse health markets.

Pathomics Health, headquartered in Singapore, operates licensed, CAP-accredited molecular laboratories and offers a growing suite of genomic and proteomic diagnostics. The company has expanded rapidly through partnerships in Malaysia, Thailand, the Philippines, and Mongolia, and is recognized for bringing clinically meaningful innovation to underserved health areas such as early cancer detection, diabetes-related kidney decline, and neurodegenerative risk profiling.

Lifenome's science-backed longevity and precision health platform is an ideal fit with our diagnostic capabilities and Southeast Asia's unmet demand for prevention-first healthcare," said Dr. Ron Tan, CEO of Pathomics Health.

The precision health market in Southeast Asia is poised for rapid growth. According to industry estimates, the ASEAN precision medicine market is projected to exceed USD $14.5 billion by 2030, driven by rising chronic disease burdens, increasing health literacy, and government investments in genomic initiatives. Countries such as Singapore, Malaysia, and Thailand are emerging as hubs for personalized medicine, while Indonesia and the Philippines represent untapped markets with vast population bases.

This partnership will initially focus on co-launching a suite of longevity and wellness panels, polygenic risk assessments, and nutrigenomics services, leveraging Lifenome's validated algorithms trained on over 900,000 individuals globally. These will be locally adapted and clinically integrated through Pathomics' regional lab network and clinical partnerships. Additional applications in women's health, cardiovascular risk reduction, and metabolic optimization are also in development.

About Lifenome
LifeNome (https://www.lifenome.com/) is the world's first B2B(2C) Longevity Operating System (Longevity OS™), an AI-powered platform that integrates multi-omics data (genomics, epigenetics, microbiome, wearable data, and biomarkers) to deliver personalized health, wellness, and longevity solutions at scale.

About Pathomics Health
Pathomics Health (https://pathomicshealth.com/) is a Singapore-based diagnostics and precision medicine company focused on molecular testing and personalized health applications in oncology, cardiometabolic diseases, infectious diseases, and neurological conditions. With CAP accreditation and an expanding footprint in ASEAN countries, Pathomics is redefining health access through innovation.